Suppr超能文献

细胞质内 Shiga 毒素 B 亚基的易位不需要逆行转运。

Retrograde transport is not required for cytosolic translocation of the B-subunit of Shiga toxin.

机构信息

Institut Curie, PSL Research University, Endocytic Trafficking and Therapeutic Delivery Group, 26 rue d'Ulm, Paris Cedex 05 75248, France CNRS UMR3666, Paris 75005, France INSERM U1143, Paris 75005, France.

INSERM U970, PARCC Université Paris Descartes Sorbonne Paris Cité, Paris 75006, France Hôpital Européen Georges-Pompidou, AP-HP, Service d'Immunologie Biologique, Paris Cedex 15 75908, France.

出版信息

J Cell Sci. 2015 Jul 1;128(13):2373-87. doi: 10.1242/jcs.169383. Epub 2015 May 14.

Abstract

Antigen-presenting cells have the remarkable capacity to transfer exogenous antigens to the cytosol for processing by proteasomes and subsequent presentation on major histocompatibility complex class-I (MHC-I) molecules, a process termed cross-presentation. This is the target of biomedical approaches that aim to trigger a therapeutic immune response. The receptor-binding B-subunit of Shiga toxin (STxB) has been developed as an antigen delivery tool for such immunotherapy applications. In this study, we have analyzed pathways and trafficking factors that are involved in this process. A covalent conjugate between STxB and saporin was generated to quantitatively sample the membrane translocation step to the cytosol in differentiated monocyte-derived THP-1 cells. We have found that retrograde trafficking to the Golgi complex was not required for STxB-saporin translocation to the cytosol or for STxB-dependent antigen cross-presentation. Depletion of endosomal Rab7 inhibited, and lowering membrane cholesterol levels favored STxB-saporin translocation. Interestingly, experiments with reducible and non-reducible linker-arm-STxB conjugates led to the conclusion that after translocation, STxB remains associated with the cytosolic membrane leaflet. In summary, we report new facets of the endosomal escape process bearing relevance to antigen cross-presentation.

摘要

抗原提呈细胞具有将外源性抗原转移到细胞质中进行蛋白酶体处理并随后在主要组织相容性复合体 I 类 (MHC-I) 分子上呈递的非凡能力,这一过程称为交叉呈递。这是生物医学方法的目标,旨在触发治疗性免疫反应。志贺毒素 (STx) 的受体结合 B 亚基已被开发为用于此类免疫治疗应用的抗原递呈工具。在这项研究中,我们分析了参与该过程的途径和运输因子。生成 STxB 和丝氨酸蛋白酶抑制剂的共价缀合物,以定量采样分化的单核细胞衍生的 THP-1 细胞中质膜向细胞质的易位步骤。我们发现,内质网 Rab7 的逆行运输对于 STxB-丝氨酸蛋白酶抑制剂向细胞质的易位或 STxB 依赖性抗原交叉呈递不是必需的。内体 Rab7 的耗尽抑制了 STxB-丝氨酸蛋白酶抑制剂的易位,并且降低膜胆固醇水平有利于 STxB-丝氨酸蛋白酶抑制剂的易位。有趣的是,具有可还原和不可还原连接臂-STxB 缀合物的实验得出的结论是,易位后,STxB 仍然与细胞质膜小叶结合。总之,我们报告了与抗原交叉呈递相关的内体逃逸过程的新方面。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验